<?xml version="1.0" encoding="UTF-8"?>
<p id="p0115">In the absence of specific anti-COVID-19 therapeutics, the major treatment regime is directed on targeting the symptoms [
 <xref rid="bib73" ref-type="bibr">73</xref>]. Immunomodulatory activity to several compounds detected in the ‘BhAVI-23’ infusion such as butanal, 3-methylhexanal, 2-hexenal, β-myrcene, gamma-terpinene, terpinen-4-ol and α-terpineol is also reported [
 <xref rid="bib74" ref-type="bibr">74</xref>]. Immunity is known to play a vital role in COVID-19 pathogenesis in early non-severe as well as during the severe stage of the disease. Corona viruses are proficient in eluding immune detection and weakening the immune responses [
 <xref rid="bib75" ref-type="bibr">75</xref>,
 <xref rid="bib76" ref-type="bibr">76</xref>]. Thus, the treatments targeting immune system could potentially help COVID-19 affected patients.
</p>
